NCT03188874 Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
| NCT ID | NCT03188874 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Technische Universität Dresden |
| Condition | Acute Myeloid Leukemia (AML) |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2010-09 |
| Primary Completion | 2030-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2010-09 with a primary completion date of 2030-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia. Investigator's sites: 60 sites in Germany. Primary objectives: * Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry. * Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS) * Documentation of treatment strategy
Eligibility Criteria
Inclusion Criteria: * AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia * Age ≥ 18 years. There is no upper age limit. * Signed written informed consent Exclusion Criteria: * there are no exclusion criteria
Contact & Investigator
Christoph Röllig, Prof. Dr.
✉ christoph.roellig@uniklinikum-dresden.deChristoph Röllig, Prof. Dr.
STUDY DIRECTOR
Universitätsklinikum Carl Gustav Carus
Frequently Asked Questions
Who can join the NCT03188874 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myeloid Leukemia (AML). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03188874 currently recruiting?
Yes, NCT03188874 is actively recruiting participants. Contact the research team at christoph.roellig@uniklinikum-dresden.de for enrollment information.
Where is the NCT03188874 trial being conducted?
This trial is being conducted at Baden-Baden, Germany, Heidelberg, Germany, Mannheim, Germany, Schwäbisch Hall, Germany and 11 additional locations.
Who is sponsoring the NCT03188874 clinical trial?
NCT03188874 is sponsored by Technische Universität Dresden. The principal investigator is Christoph Röllig, Prof. Dr. at Universitätsklinikum Carl Gustav Carus. The trial plans to enroll 15,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.